Latest News and Press Releases

Want to stay updated on the latest news?

Sign into Reader Account Create Reader Account

May 21, 2025 08:00 ET | Source: Galimedix Therapeutics, Inc.

Galimedix Therapeutics publishes new data in peer-reviewed International Journal of Molecular Sciences demonstrating disease-modifying capability of GAL-201 in Alzheimer’s disease

Maintains Brain Connectivity: GAL-201 prevents amyloid-beta (Aβ)–induced synaptic damage by maintaining long-term potentiation, a correlate for learning and memory.Improves Memory and Behavior:...
June 20, 2024 16:30 ET | Source: Cellectis Inc.

Cellectis Publishes a Scientific Article Unveiling Three Key Factors for Efficient TALE Base Editing

NEW YORK, June 20, 2024 (GLOBE NEWSWIRE) -- Cellectis (the “Company”) (Euronext Growth: ALCLS - NASDAQ: CLLS), a clinical-stage biotechnology company using its pioneering gene-editing platform to...
February 08, 2024 16:02 ET | Source: Athira Pharma, Inc.

Athira Pharma Announces Publication in Frontiers in Neuroscience Highlighting Therapeutic Potential of ATH-1105 in Amyotrophic Lateral Sclerosis (ALS)

Athira Pharma Announces Publication in Frontiers in Neuroscience Highlighting Therapeutic Potential of ATH-1105 in Amyotrophic Lateral Sclerosis (ALS)
January 31, 2024 05:00 ET | Source: AKAMPION

MetrioPharm veröffentlicht Studiendaten, die die Wirkung einer Host-Directed Therapy in COVID-19 zeigen

Ergebnisse stammen aus der klinischen Studie CT-05 an 131 hospitalisierten Patienten mit COVID-19Die Daten zeigen, dass MetrioPharms Leitsubstanz MP1032 eine mit Remdesivir vergleichbare Wirksamkeit...
January 31, 2024 05:00 ET | Source: AKAMPION

MetrioPharm Publishes First Trial Data Showing Effects of Host-Directed Therapy in COVID-19

Results of clinical trial CT-05 in 131 hospitalized patients with COVID-19Trial data demonstrate that MetrioPharm´s lead compound MP1032 has comparable efficacy to remdesivir with several additional...
May 24, 2023 11:30 ET | Source: ONWARD Medical

L’interface cerveau-ordinateur (BCI) permet une marche contrôlée par la pensée après une lésion médullaire

EINDHOVEN, Pays-Bas, 24 mai 2023 (GLOBE NEWSWIRE) -- ONWARD Medical N.V. (Euronext : ONWD), l’entreprise de technologie médicale spécialisée dans le développement de thérapies innovantes de...
May 24, 2023 11:30 ET | Source: ONWARD Medical

Brain Computer Interface (BCI) maakt gedachtegestuurd lopen mogelijk na ruggenmergletsel

EINDHOVEN, Nederland, May 24, 2023 (GLOBE NEWSWIRE) -- ONWARD Medical N.V. (Euronext: ONWD), het medische technologiebedrijf dat innovatieve ruggenmergstimulatietherapieën ontwikkelt om beweging,...
May 24, 2023 11:30 ET | Source: ONWARD Medical

Brain-Computer-Interface (BCI) ermöglicht durch Gedanken gesteuertes Gehen nach Rückenmarksverletzung

EINDHOVEN, Niederlande, May 24, 2023 (GLOBE NEWSWIRE) -- Das Medizintechnikunternehmen ONWARD Medical N.V. (Euronext: ONWD), das innovative Therapien zur Wiederherstellung von Bewegung,...
May 24, 2023 11:30 ET | Source: ONWARD Medical

Brain Computer Interface (BCI) Enables Thought-Controlled Walking after Spinal Cord Injury

EINDHOVEN, the Netherlands, May 24, 2023 (GLOBE NEWSWIRE) -- ONWARD Medical N.V. (Euronext: ONWD), the medical technology company creating innovative spinal cord stimulation therapies to restore...